U.S. markets closed

Hancock Jaffe Laboratories, Inc. (HJLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.40+0.21 (+3.39%)
At close: 4:00PM EST

Hancock Jaffe Laboratories, Inc.

70 Doppler
Irvine, CA 92618
United States
949 261 2900
http://www.hancockjaffe.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert A. BermanCEO & Director415.81kN/A1963
Mr. Craig Thomas GlynnCFO & Treasurer143kN/A1961
Dr. Marc H. GlickmanSr. VP & Chief Medical Officer403.98kN/A1949
Mr. Warren HancockCo-founderN/AN/AN/A
Dr. Benedict Broennimann M.D.Chief Medical Officer of Outside of United StatesN/AN/A1957
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. operates as a subsidiary of Leman Cardiovascular SA.

Corporate Governance

Hancock Jaffe Laboratories, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.